Pharmaceutical industry, purchase of consciences and bioethics
Keywords:
Bioethics, primary care, health, PHC
Abstract
Cooperation between industry and health has always been present with the objective of contributing in different medical areas. But due to the interest of the industry in increasing its profits, the relationship with doctors has been redefined and it has been shown that the "Big Pharma" invests in professionals so that they are the merchants of their products.
Downloads
Download data is not yet available.
References
1. Organización Mundial de la Salud (OMS). Declaración de la OMS en relación con las denuncias de conflictos de intereses y la «falsa» pandemia [Internet]. 2010. Available from: https://www.who.int/mediacentre/news/statements/2010/h1n1_pandemic_20100122/es/
2. Novella S. Demonizing “Big Pharma” [Internet]. Science-Based Medicine. 2010. Available from: https://sciencebasedmedicine.org/demonizing-big-pharma/
3. Blaskiewicz R. The Big Pharma conspiracy theory. Med Writ. 2013;22(4):259–61.
4. DeAngelis CD. Big Pharma Profits and the Public Loses. Milbank Q. 2016;94(1):30–3.
5. Tiller L. Getting Their Fix: Doctor’s Dependency on Big Pharma. Bus. Entrep Tax L. 2018;2:492.
6. Moynihan R. Education and debate between doctors and drug companies . 1 : Entanglement. Bmj. 2003;326(May):1189–92.
7. De Lotbiniere-Bassett MP, McDonald PJ. Industry Financial Relationships in Neurosurgery in 2015: Analysis of the Sunshine Act Open Payments Database. World Neurosurg [Internet]. 2018;114:e920–5. Available from: https://doi.org/10.1016/j.wneu.2018.03.116
8. Robbins NM, Meyer MJ, Bernat JL. Scope and Nature of Financial Conflicts of Interest Between Neurologists and Industry: 2013-2016. Neurology [Internet]. 2019;93(10):438–49. Available from: https://pubmed.ncbi.nlm.nih.gov/31383793-scope-and-nature-of-financial-conflicts-of-interest-between-neurologists-and-industry-2013-2016/
9. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology. 2018;90(23):1063–70.
10. Bernat JL, Swash M. Relationships between neurologists and industry. Neurology. 2018;90(23):1047–8.
11. Orthopaedic A, Orthopaedic A, Task M, Relationships S. American Orthopaedic Association Orthopaedic Institute of Medicine Report from the Task Force on Surgeon-Industry Relationships in the Discipline of Orthopaedic Surgery. J Bone Joint Surg Am. 2012;89(1):10–2.
12. Iyer S, Derman P, Sandhu HS. Orthopaedics and the physician payments sunshine act an examination of payments to U.S. Orthopaedic surgeons in the open payments database. J Bone Jt Surg - Am Vol. 2016;98(5):e18.
13. Teplitsky S, Perez T, Leong JY, Xie K, Murphy A, Shenot PJ. Industry payments to female pelvic medicine and reconstructive surgeons: an analysis of Sunshine Act open payments from 2014–2017. Int Urogynecol J. 2019;
14. Muffly TM, Giamberardino WL, Guido J, Weterings R, Bastow B, Sheeder J. Industry payments to obstetricians and gynecologists under the sunshine act. Obstet Gynecol. 2018;132(1):9–17.
15. Chao AH, Gangopadhyay N. Industry financial relationships in plastic surgery: Analysis of the sunshine act open payments database. Plast Reconstr Surg. 2016;138(2):341e-348e.
16. Probst P, Grummich K, Ulrich A, Büchler MW, Knebel P, Diener MK. Association of industry sponsorship and positive outcome in randomised controlled trials in general and abdominal surgery: Protocol for a systematic review and empirical study. Syst Rev. 2014;3(1):1–6.
17. Luce EA. Financial conflicts of interest in plastic surgery: Background, potential for bias, disclosure, and transparency. Plast Reconstr Surg. 2015;135(4):1149–55.
18. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. J Natl Cancer Inst. 2016;108(12):1–10.
19. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: Retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019;367:1–9.
2. Novella S. Demonizing “Big Pharma” [Internet]. Science-Based Medicine. 2010. Available from: https://sciencebasedmedicine.org/demonizing-big-pharma/
3. Blaskiewicz R. The Big Pharma conspiracy theory. Med Writ. 2013;22(4):259–61.
4. DeAngelis CD. Big Pharma Profits and the Public Loses. Milbank Q. 2016;94(1):30–3.
5. Tiller L. Getting Their Fix: Doctor’s Dependency on Big Pharma. Bus. Entrep Tax L. 2018;2:492.
6. Moynihan R. Education and debate between doctors and drug companies . 1 : Entanglement. Bmj. 2003;326(May):1189–92.
7. De Lotbiniere-Bassett MP, McDonald PJ. Industry Financial Relationships in Neurosurgery in 2015: Analysis of the Sunshine Act Open Payments Database. World Neurosurg [Internet]. 2018;114:e920–5. Available from: https://doi.org/10.1016/j.wneu.2018.03.116
8. Robbins NM, Meyer MJ, Bernat JL. Scope and Nature of Financial Conflicts of Interest Between Neurologists and Industry: 2013-2016. Neurology [Internet]. 2019;93(10):438–49. Available from: https://pubmed.ncbi.nlm.nih.gov/31383793-scope-and-nature-of-financial-conflicts-of-interest-between-neurologists-and-industry-2013-2016/
9. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology. 2018;90(23):1063–70.
10. Bernat JL, Swash M. Relationships between neurologists and industry. Neurology. 2018;90(23):1047–8.
11. Orthopaedic A, Orthopaedic A, Task M, Relationships S. American Orthopaedic Association Orthopaedic Institute of Medicine Report from the Task Force on Surgeon-Industry Relationships in the Discipline of Orthopaedic Surgery. J Bone Joint Surg Am. 2012;89(1):10–2.
12. Iyer S, Derman P, Sandhu HS. Orthopaedics and the physician payments sunshine act an examination of payments to U.S. Orthopaedic surgeons in the open payments database. J Bone Jt Surg - Am Vol. 2016;98(5):e18.
13. Teplitsky S, Perez T, Leong JY, Xie K, Murphy A, Shenot PJ. Industry payments to female pelvic medicine and reconstructive surgeons: an analysis of Sunshine Act open payments from 2014–2017. Int Urogynecol J. 2019;
14. Muffly TM, Giamberardino WL, Guido J, Weterings R, Bastow B, Sheeder J. Industry payments to obstetricians and gynecologists under the sunshine act. Obstet Gynecol. 2018;132(1):9–17.
15. Chao AH, Gangopadhyay N. Industry financial relationships in plastic surgery: Analysis of the sunshine act open payments database. Plast Reconstr Surg. 2016;138(2):341e-348e.
16. Probst P, Grummich K, Ulrich A, Büchler MW, Knebel P, Diener MK. Association of industry sponsorship and positive outcome in randomised controlled trials in general and abdominal surgery: Protocol for a systematic review and empirical study. Syst Rev. 2014;3(1):1–6.
17. Luce EA. Financial conflicts of interest in plastic surgery: Background, potential for bias, disclosure, and transparency. Plast Reconstr Surg. 2015;135(4):1149–55.
18. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. J Natl Cancer Inst. 2016;108(12):1–10.
19. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: Retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019;367:1–9.
Published
2019-11-30
How to Cite
1.
Simancas-Racines D, Zambrano-Achig P, Montesinos C. Pharmaceutical industry, purchase of consciences and bioethics. PFR [Internet]. 2019Nov.30 [cited 2025Jul.1];4(3). Available from: https://practicafamiliarrural.org/index.php/pfr/article/view/120
Section
Artículos Originales
Copyright (c) 2019 Rural Family Practice
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
